New patent application published for: ELUENT FOR SEPARATING HEMOGLOBIN AND METHOD FOR SEPARATING SAME
ELUENT FOR SEPARATING HEMOGLOBIN AND METHOD FOR SEPARATING SAME
Abstract
The present invention provides: an eluent which is passed, in an analysis of a hemoglobin mixture using cation exchange chromatography, when separating/analyzing at least one of hemoglobin A2 or abnormal hemoglobin E, D, S, or C from hemoglobin A0, and which comprises at least one acid selected from among hydrochloric acid, sulfuric acid, and carboxylic acids which are kosmotropic salts in the Hofmeister series or salts having a structure similar to thereto; and a method using the eluent.
Inventors:
MEGURO; Tomohiro (Shunan-shi, Yamaguchi, JP), SASAKI; Yusuke (Shunan-shi, Yamaguchi, JP), OGINO; Shinji (Shunan-shi, Yamaguchi, JP)
Applicant:
TOSOH CORPORATION (Shunan-shi, Yamaguchi, JP)
Family ID:
1000009500611
Assignee:
TOSOH CORPORATION (Shunan-shi, Yamaguchi, JP)
Appl. No.:
19/486543
Filed (or PCT Filed):
May 24, 2023
PCT No.:
PCT/JP2023/019317
Claims
1: An eluent to be used during analysis of a hemoglobin mixture using cation-exchange chromatography, for analysis of hemoglobin components that elute after the hemoglobin A0 component, the eluent being passed through for separation and analysis of at least one from among abnormal hemoglobin E, D, S, C or hemoglobin A2 from the hemoglobin A0 component, and the eluent comprising one or more selected from among salts of carboxylic acids, hydrochloric acid and sulfuric acid, which are kosmotropic salts of the Hofmeister series, or salt species having structures similar to them.
2: The eluent according to claim 1, wherein the kosmotropic salt includes one or more selected from among salts of acetic acid, succinic acid and hydroxycarboxylic acids.
3: The eluent according to claim 1, wherein the kosmotropic salt is a salt of citric acid.
4: The eluent according to claim 1, wherein the kosmotropic salt is a carboxylic acid salt, and which is passed through when separating and analyzing hemoglobin A0 and A2.
5: The eluent according to claim 4, wherein the kosmotropic salt is selected from among one or more salts of malonic acid, fumaric acid and hydroxycarboxylic acids.
6: The eluent according to claim 4, wherein the kosmotropic salt is a salt of citric acid.
7: A method using an eluent according to claim 1, wherein at least one of the abnormal hemoglobins E, D, S, C or hemoglobin A2 is separated and analyzed from the hemoglobin A0 component.
8: An analysis method using an eluent according to claim 1, wherein: in addition to the eluent according to claim 1 which is passed through when separating and analyzing hemoglobin A0 from abnormal hemoglobin E or A2, at least one eluent with weaker elution strength than that eluent is passed through to separate and elute out the hemoglobin components that elute before the A0 component, and after either or both hemoglobin F and hemoglobin A1c are separated and eluted, the eluent according to claim 1 is passed through to separate and elute out the hemoglobin A0 from the abnormal hemoglobin E or A2.
- Company
- TOSOH CORPORATION
- Keywords
- G01N30/96, G01N30/34, G01N30/88, G01N33/721